retatrutide type 2 diabetes phase 2 lancet 2023 rosenstock Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Triple hormone receptor agonist retatrutide
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14

00092-0/asset/68240365-3bb7-461d-91f9-d644c6b9c749/main.assets/gr3.jpg)





















:max_bytes(150000):strip_icc()/GettyImages-2169095535-f8d8276415dd4300a867a1f8b7de098f.jpg)





